NPC(SH:600713) Shang Hai Zheng Quan Bao·2026-02-27 20:31Core Viewpoint - The announcement details the completion of a share transfer involving 11.04% of Nanjing Pharmaceutical Group Co., Ltd. from Alliance Healthcare Asia Pacific Limited to Guangzhou Guangyao Phase II Fund, with no change in control or significant impact on the company's governance structure [2][3][7]. Group 1: Share Transfer Details - On September 26, 2025, Alliance Healthcare signed a share transfer agreement to sell 144,557,431 shares (11.04% of total shares) to Guangzhou Guangyao Phase II Fund at a price of 5.18 RMB per share, totaling approximately 748.81 million RMB [2][4]. - Following the transfer, Alliance Healthcare no longer holds shares in the company, while Guangzhou Guangyao Phase II Fund now holds the aforementioned shares [2][4]. Group 2: Regulatory Approvals - On November 17, 2025, the company received a notice confirming that Guangzhou Guangyao Phase II Fund obtained approval from its state-owned asset supervisor, Guangzhou Pharmaceutical Group Co., Ltd., for the share acquisition [5]. - The share transfer was officially registered on February 27, 2026, with the transfer date being February 26, 2026, confirming the completion of the transaction [6]. Group 3: Impact and Commitments - The share transfer will not result in a change of the company's controlling shareholder or actual controller, nor will it trigger a mandatory bid or significantly affect the company's governance and ongoing operations [3][7]. - Guangzhou Guangyao Phase II Fund has committed not to transfer the acquired shares for 18 months, except to entities controlled by Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., and this commitment also applies to any shares derived from stock dividends or capital increases during this period [7].